AlphaMark Advisors LLC Purchases 940 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

AlphaMark Advisors LLC grew its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 1,880.0% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 990 shares of the medical equipment provider’s stock after acquiring an additional 940 shares during the quarter. AlphaMark Advisors LLC’s holdings in Zimmer Biomet were worth $131,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently modified their holdings of ZBH. AMI Investment Management Inc. acquired a new position in Zimmer Biomet during the 1st quarter valued at about $210,000. Cornerstone Wealth Group LLC purchased a new position in shares of Zimmer Biomet during the first quarter valued at approximately $425,000. Romano Brothers AND Company grew its holdings in Zimmer Biomet by 1.1% during the first quarter. Romano Brothers AND Company now owns 9,514 shares of the medical equipment provider’s stock worth $1,256,000 after buying an additional 100 shares in the last quarter. AMF Tjanstepension AB purchased a new stake in Zimmer Biomet in the 1st quarter valued at $30,300,000. Finally, Wealth Enhancement Advisory Services LLC lifted its stake in Zimmer Biomet by 22.5% during the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 15,346 shares of the medical equipment provider’s stock valued at $2,025,000 after acquiring an additional 2,820 shares in the last quarter. 88.89% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts have recently commented on the stock. Barclays lowered their target price on shares of Zimmer Biomet from $130.00 to $125.00 and set an “underweight” rating for the company in a report on Friday, May 31st. Needham & Company LLC reiterated a “hold” rating on shares of Zimmer Biomet in a research note on Thursday, May 30th. Piper Sandler downgraded Zimmer Biomet from an “overweight” rating to a “neutral” rating and cut their target price for the stock from $140.00 to $115.00 in a research note on Monday. Evercore ISI increased their price target on Zimmer Biomet from $125.00 to $130.00 and gave the company an “in-line” rating in a research report on Thursday, April 4th. Finally, Argus raised Zimmer Biomet from a “hold” rating to a “buy” rating and set a $150.00 price objective on the stock in a research report on Tuesday, May 21st. One investment analyst has rated the stock with a sell rating, ten have issued a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, Zimmer Biomet presently has an average rating of “Hold” and a consensus price target of $132.65.

Zimmer Biomet Stock Performance

NYSE:ZBH traded down $2.57 on Monday, reaching $105.96. 2,327,708 shares of the company’s stock were exchanged, compared to its average volume of 1,509,971. The firm has a market cap of $21.80 billion, a price-to-earnings ratio of 22.94, a P/E/G ratio of 1.95 and a beta of 1.01. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.66 and a quick ratio of 0.80. The stock has a fifty day simple moving average of $115.29 and a 200-day simple moving average of $121.22. Zimmer Biomet Holdings, Inc. has a 52 week low of $102.00 and a 52 week high of $144.80.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings data on Thursday, May 2nd. The medical equipment provider reported $1.94 EPS for the quarter, topping the consensus estimate of $1.87 by $0.07. Zimmer Biomet had a net margin of 12.93% and a return on equity of 12.70%. The company had revenue of $1.89 billion during the quarter, compared to the consensus estimate of $1.87 billion. During the same period last year, the firm earned $1.89 EPS. Zimmer Biomet’s revenue for the quarter was up 3.2% on a year-over-year basis. As a group, sell-side analysts predict that Zimmer Biomet Holdings, Inc. will post 8.1 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 31st. Investors of record on Wednesday, June 26th will be paid a dividend of $0.24 per share. The ex-dividend date of this dividend is Wednesday, June 26th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.91%. Zimmer Biomet’s payout ratio is 20.78%.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.